Savant Capital LLC Has $130,000 Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Savant Capital LLC cut its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 48.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,882 shares of the company’s stock after selling 12,956 shares during the period. Savant Capital LLC’s holdings in Syndax Pharmaceuticals were worth $130,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Phoenix Financial Ltd. acquired a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $701,000. Exome Asset Management LLC raised its holdings in Syndax Pharmaceuticals by 5.7% in the 1st quarter. Exome Asset Management LLC now owns 337,198 shares of the company’s stock valued at $4,142,000 after acquiring an additional 18,298 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Syndax Pharmaceuticals by 127.7% in the 1st quarter. Deutsche Bank AG now owns 204,732 shares of the company’s stock worth $2,516,000 after acquiring an additional 114,828 shares during the period. Aberdeen Group plc lifted its position in shares of Syndax Pharmaceuticals by 129.1% in the 2nd quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock worth $2,842,000 after acquiring an additional 170,993 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $2,593,000.

Analysts Set New Price Targets

A number of brokerages recently commented on SNDX. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday. JPMorgan Chase & Co. dropped their price objective on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Syndax Pharmaceuticals in a research report on Monday, October 27th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, Barclays raised their price target on shares of Syndax Pharmaceuticals from $19.00 to $22.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $35.90.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $16.41, for a total value of $2,581,407.87. Following the completion of the transaction, the chief executive officer owned 298,661 shares in the company, valued at approximately $4,901,027.01. The trade was a 34.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:SNDX opened at $17.05 on Friday. The company’s fifty day moving average is $15.35 and its 200-day moving average is $12.87. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $18.00. The company has a market capitalization of $1.48 billion, a PE ratio of -4.38 and a beta of 0.73.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.04. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business had revenue of $45.87 million during the quarter, compared to analysts’ expectations of $49.08 million. During the same quarter last year, the company posted ($0.98) EPS. The firm’s revenue for the quarter was up 266.4% on a year-over-year basis. Equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).